Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 18/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 9/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2892832 | 0.93 | BRAF (0.47) | BRAFCYP3A4LCKRAF1 | |
| SCHEMBL2891097 | 0.90 | BRAF (0.51) | BRAFCYP3A4LCKRAF1 | |
| SCHEMBL2893883 | 0.90 | BRAF (0.68) | BRAFCYP3A4LCKRAF1 | |
| SCHEMBL2892919 | 0.86 | BRAF (0.52) | BRAFRAF1 | |
| SCHEMBL2891886 | 0.86 | BRAF (0.51) | BRAFLCKRAF1 | |
| SCHEMBL2895495 | 0.86 | BRAF (0.53) | BRAFCYP3A4LCKRAF1 | |
| SCHEMBL2893492 | 0.84 | BRAF (0.51) | BRAFRAF1 | |
| SCHEMBL2892968 | 0.84 | NPC1 (0.51) | BRAFLCKRAF1 | |
| SCHEMBL2897957 | 0.83 | BRAF (0.56) | BRAFLCKRAF1 | |
| SCHEMBL2886046 | 0.82 | BRAF (0.54) | BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614330-B2 | Substituted benz-azoles and methods of their use as inhibitors of RAF kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-8299108-B2 | for treatment of hematological/hormone-dependent cancer | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-20100196368-A1 | SUBSTITUTED BENZ-AZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7728010-B2 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1499311-B1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20070299039-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | CHIRON CORPORATION (US) | 2007-12-27 | — | — | US | disclosed |
| US-7071216-B2 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | CHIRON CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | BRAF, RAF1, ARAF | BRAF 1/4885CYP3A4 1457/4885LCK 250/4885 |
| US-20100196368-A1 | SUBSTITUTED BENZ-AZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | BRAF, RAF1, ARAF | BRAF 1/4885CYP3A4 1382/4885LCK 198/4885 |
| US-20070299039-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | BRAF 1/4885CYP3A4 1382/4885LCK 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.